A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Troeung, Lakkhina ^a   Egan, Sarah J ^a   Gasson, Natalie ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; OMEGA 3 FATTY ACID; PAROXETINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; SELEGILINE; SERTRALINE; TIANEPTINE; TRAZODONE; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COUNSELING; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; ELECTROACUPUNCTURE; HUMAN; META ANALYSIS; MONOTHERAPY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION;

ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; HUMANS; PARKINSON DISEASE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84893368046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079510     Document Type: Article

References (79)

1. Weintraub D, Burn DJ (2011) Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord, 26: 1022-1031.
2. Negre-Pages L, Grandjean H, Lapeyre-Mestre M, Montasruc JL, Fourrier A, et al. (2010) Anxious and depressive symptoms in Parkinson's disease: the French cross-sectional DoPAMiP study. Mov Disord, 25: 157-166.
3. Carod-Artal FJ, Ziomkowski S, Mesquita HM, Martinez-Martin P (2008) Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with parkinson's disease. Parkinsonism and Relat D, 14: 102-108.
4. Hely M, Morris JG, Reid WG, Trafficante R (2005) Sydney multicentre study of parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord, 20:190-199.
5. Frisina PG, Borod JC, Foldi NS, Tenenbaum HR (2008) Depression in parkinson's disease: health risks, etiology and treatment options. Neuropsychiatr Dis Treat, 4: 81-91.
6. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, et al. (2007) Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiat Neurol, 20: 161-165.
7. Hauser RA, Zesiewicz TA (1997) Sertraline for the treatment of depression in Parkinson's disease. Mov Disord, 12; 756-759.
8. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Gironell A, Garcia-Sanchez C, et al. (2008) Motor changes during sertraline treatment in depressed patients with parkinson's disease. Euro J Neurol, 15: 953-959.
9. Marino L, Friedman J (2013) Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in parkinson's disease. Int J Neurosci, 123: 70-71.
10. Menza M, Marin H, Kaufman K, Mark M, Lauritano M (2004) Citalopram treatment of depression in parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci, 16: 315-319.
11. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, et al. (2001) Tolerability of paroxetine in parkinson's disease: a prospective study. Mov Disord, 15: 986-989.
12. Verma R, Anand K (2012) Efficacy and tolerability of escitalopram for treating depression in parkinson's disease. Delhi Psychiatry J, 15: 57-63.
13. Weintraub D, Taraborelli D, Morales KH, Duda JEF, Katz IR, et al. (2006) Escitalopram for major depression in parkinson's disease: an open-label flexible dosage study. J Neuropsychiatry Clin Neurosci, 18: 377-383.
14. Alca A, Mehmet AK, Sutcugil L (2011) Comparison of sertraline and venlafaxine treatments for depression in Parkinson's disease. Noropsikiyatri Arsivi 48: 201-206.
15. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE (1980) Antidepressive treatment in parkinson's disease: a controlled trial of the effect of Nortriptyline in patients with parkinson's disease treated with l-dopa. Acta Neurol Scand, 62: 210-219.
16. Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, et al. (2006) Randomized study of sertraline and low-dose amitriptyline in patients with parkinson's disease and depression: effect on quality of life. Mov Disord, 21: 1119-1122.
17. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, et al. (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord, 23: 850-857.
18. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR (2003) SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr.Psychiatry, 18: 552-554.
19. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, et al. (2009) A controlled trial of antidepressants in patients with Parkinson's disease and depression. Neurology, 72: 886-992.
20. Richard I, McDermott MP, Kurlan JM, Lyness JM, Como PG, et al. (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in parkinson's disease. Neurology, 78: 1314-1322.
21. Serrano-Duenas M (2002) A comparison between low doses of amitriptyline and low doses of fluoxetine used in the control of depression in patients suffering from parkinson's disease. Rev Neurol, 35: 1010-1014.
22. Wermuth L, Sorensen PS, Timm S, Christensen B, Utzon NP, et al. (1988) Depression in idiopathic parkinson's disease treated with citalopram: a placebocontrolled trial. Nord J Psychiatry, 52: 163-169.
23. Xia Y, Wang HD, Ding Y, Kang B, Liu WG (2012) Parkinson's disease combined with depression treated with electroacupuncture and medication and its effect on serum. Chin Acupuncture and Moxibustion, 32: 1071-1074.
24. Rocha FL, Murad MGR, Stumpf B, Hara C, Fuzikawa C (2013) Antidepresssants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol, 27: 417-423.
25. Marsh L (2000) Anxiety disorders in parkinson's disease. Int Rev Psychiatry, 12: 307-318.
26. Muller T (2002) Drug treatment of non-motor symptoms in parkinson's disease. Expert Opinion on Pharmacotherapy, 3: 381-388.
27. Vajda FJE, Solinas C (2005) Current approaches to management of depression in parkinson's disease. J Clin Neurosci, 12: 739-743.
28. Leentjens AFG, Koester J, Fruh B, Shephard TS, Barone P, et al. (2009) The effect of pramipexole on mood and motivational symptoms in parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Therapeutics, 31: 89-98.
29. Kano O, Ikeda K, Kiyozuka T, Iwamoto K, Ito H, et al. (2008) Beneficial effect of pramipexole for motor function and depression in parkinson's disease. J Neuro Dis Treat, 4: 707-710.
30. Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia, and motor functioning in parkinson's disease. J Neurol Sci, 248: 266-270.
31. Lemke MR, Brecht HM, Koester J, Reichmann H (2005) Anhedonia, depression, and motor functioning in parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci, 17: 214-220.
32. Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, et al. (2003) Pramipexole and pergolide in the treatment of depression in parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol, 10: 399-406.
33. Barone P, Poewe W, Albrecht S, Debiuvre C, Massey D, et al. (2010) Pramipexole for the treatment of depressive symptoms in patients with parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 9: 575-580.
34. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, et al. (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. J Neurol, 253: 601-607.
35. De Lau LML, Bornebroek M, Witteman CM, Hofman A, Koudstaal PJ, et al. (2005) Dietary fatty acids and the risk of Parkinson disease: The Rotterdam study. Neurology, 54: 2040-2045.
36. Samadii P, Gregoire L, Rouillard C, Bedard PJ, Di Paolo T, et al. (2006) Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol, 59: 282-288.
37. Moralez Da Silva T, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, et al. (2008) Depression in Parkinson's disease: A double-blind, randomized, placebocontrolled pilot study of omega-3 fatty-acid supplementation. J Aff Disord, 111: 351-359.
38. Chen R (2010) Repetitive transcranial magnetic stimulation as treatment for depression in Parkinson's disease. Mov Disord, 25: 2272-2273.
39. Epstein CM, Evatt ML, Funk A, Girard-Siqueira L, Lupei N, et al. (2007) An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease. Clin Neurophys, 118: 2189-2194.
40. Dragasevic N, Potrebic A, Damjanovic A, Stefanova E, Kostic V (2002) Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: An open study. Mov Disord, 17: 528-532.
41. Kormos TC (2007) Efficacy of rTMS in the treatment of co-morbid anxiety in depressed patients with Parkinson's disease. Mov Disord, 22: 1836-1840.
42. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, et al. (2004) Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neuro Neurosur Psychiat, 75: 1171-1174.
43. Pal E, Nagy F, Aschermann Z, Balasz E, Kovacs N (2010) The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord, 25: 2311-2317.
44. Cole K, Vaughan FL (2005) The feasibility of using cognitive behaviour therapy for depression associated with parkinson's disease: A literature review. Parkinsonism Relat D, 11: 269 - 276.
45. Laidlaw K (2008) Cognitive Behaviour Therapy for depression in Parkinson's disease. In K. Laidlaw & B. Knight (ed's), Handbook of emotional disorders in later life: Assessment and treatment. NY: Oxford University Press.
46. Dobkin RD, Allen LA, Menza M (2006) A cognitive-behavioural treatment package for depression in Parkinson's disease. Psychosom, 47: 259-263.
47. Dobkin RD, Allen LA, Menza M (2007) Cognitive-behavioural therapy for depression in Parkinson's disease: A pilot study. Mov Disord, 22: 946-952.
48. Dobkin RD, Menza M, Allen LA, Tiu J, Friedman J, et al. (2011) Telephonebased cognitive-behavioural therapy for depression in Parkinson's disease. J Ger Psychiat Neurol, 24: 206-214.
49. Farabaugh A, Locascio JJ, Yap L, Growdown J, Fava M, et al. (2010) Cognitive-behavioural therapy for patients with Parkinson's disease and comorbid major depressive disorder. Psychosomatics, 51: 124-129.
50. Feeney F, Egan S, Gasson N (2005) Treatment of depression and anxiety in parkinson's disease: a pilot study using group cognitive behavioural therapy. Clin Psych, 9: 31 - 38.
51. Gupta R (2000) Treatment of depression in an elderly Asian Indian male: A cognitive behavioural approach. Clin Gerontol, 22: 87 - 89.
52. Heinrichs N, Hoffman EC, Hofmann SG (2001) Cognitive-behavioural treatment for social phobia in Parkinson's disease: A single-case study. Cog Behav Prac, 8: 328-335.
53. Laidlaw K, Thompson LW, Siskin-Dick L, Gallagher-Thompson D (2003) Cognitive Behavioural Therapy with Older People. Chichester: John Wiley & Sons, Ltd.
54. Mohlman J, Reel DH, Chazin D, Ong D, Georgescu B, et al. (2010) A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson's disease. Clin Case Stud, 9: 74-90.
55. Dobkin RD, Menza M, Allen LA, Gara MA, Mark M, et al. (2011) Cognitive behaviour therapy for depression in Parkinson's diseae: a randomized controlled trial. Am J Psychiatry, 168: 1066-1074.
56. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritisis P, et al. (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol, 10: 49-60.
57. Klaassen T, Verhey FR, Sneijders GH, Rozendaal N, de Vet HCW, et al. (1995) Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci, 7: 281-286.
58. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, et al. (2005). Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord, 20: 111-1169.
59. Frisina PG, Tenenbaum HR, Borod JC, Foldi NS (2008) The effects of antidepressants in Parkinson's disease: a meta-analysis. Int J Neurosci, 118: 667-682.
60. Higgins JPT, Green S (2008). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Book Series. Chichester: John Wiley & Sons Ltd.
61. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6:1-6.
62. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2010) A basic introduction to fixed effect and random-effects models for meta-analysis. Res Syn Meth, 1: 91-111.
63. DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 28: 105-114
64. Marin-Martinez F, Sanchez-Meca J (2009) Weighting by inverse variance or by sample size in random-effects meta-analysis. Educ Psychol Meas, 1: 1-18.
65. Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Orlando, Florida, Academic Press.
66. Hedges LV, Vevea JL (1988) Fixed- and random-effects models in meta-analysis. Psychol Methods, 3: 486-504.
67. DerSimonian R, Laird N (1986) Meta-analysis of clinical trials. Contemp Clin Trials, 7: 177-188.
68. Thornton A, Lee P (2000) Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol, 53: 207-216.
69. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ, 315: 629-634.
70. Rosenthal R (1979) The "file drawer problem" and tolerance for null results. Psychol Bull, 85: 638-641.
71. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta analyses. BMJ. 327: 557-560.
72. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a metaanalysis. Statist Med, 21: 1539-1558.
73. Veazey C, Cook KF, Stanley M, Lai EC, Kunik ME (2009) Telephone-administered cognitive behavioural therapy: a case study of anxiety and depression in Parkinson's disease. J Clin Psychol Med Settings, 16: 243-253.
74. Werneck ALS, Rosso AL, Vincent MB (2009) The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson's disease. Arq NeuroPsiquiatr, 67: 407-412.
75. Djokic G, Zivkovic N, Pavicevic, Lazic D (2010) Depression in Parkinson's disease - searching for the most potent antidepressant. Eur Psychiatry, 25: 249.
76. Weintraub D, Mavandadi S, Mamikonyan E, Sierowf AD, Duda JE, et al. (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology, 75: 446-455.
77. Pinquart M, Duberstein PR, Lyness JM (2007) Effects of psychotherapy and other behavioural interventions on clinically depressed older adults: a metaanalysis. Aging Ment Health, 11: 645-657.
78. National Institute of Health and Clinical Excellence (2010) Depression. The NICE Guideline on the Treatment Management of Depression in Adults. Updated Version, Great Britain, British Psychological Society and the Royal College of Psychiatrists.
79. Black KJ (2011) A new(old) treatment option for depression in Parkinson's disease. Am J Psychiatry, 168: 1015-1016.